Skip to content
value.today

OrbitalRx, Inc.

Total raised
$5 M
3 rounds on record
Latest round
$1 M
Aug 2025
First round on record
Oct 2018
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of OrbitalRx, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2025$1 MNo. 3Under $2 million

OrbitalRx, Inc.: Raise no. 3, Aug 2025

Investors in this round

22 investors had bought by the notice of Oct 20, 2025: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jason S. Gasper · Executive Officer, Director
  • Dan Hackman · Director
  • Gary S. Abrahams · Director
  • Ren S. Roome · Director
  • Robert Crutchfield · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jason Gasper, Chief Executive Officer. Newest notice filed Oct 20, 2025. Read the notice at the SEC.

equitySEC
May 2023$1 MNo. 2Under $2 million

OrbitalRx, Inc.: Raise no. 2, May 2023

Investors in this round

18 investors had bought by the notice of Oct 9, 2024: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Keith S. Heffron · Executive Officer
  • Nate Peaty · Executive Officer, Director
  • Dan Hackman · Director
  • Gary S. Abrahams · Director
  • Ren S. Roome · Director
  • Robert Crutchfield · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer has discontinued accepting new investments. The offering is closed.”

Signed by Nate Peaty, Chief Executive Officer. Newest notice filed Oct 9, 2024. Read the notice at the SEC.

equitySEC
Oct 2018$2 MNo. 1$2 to $10 million

OrbitalRx, Inc.: Raise no. 1, Oct 2018

Investors in this round

12 investors had bought by the notice of Aug 29, 2019: 11 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 504: up to $10 million in twelve months
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam Orsborn · Executive Officer, Director
  • Mayank Thanawala · Executive Officer
  • Nate Peaty · Executive Officer, Director
  • David S. Carney · Director
  • Gary S. Abrahams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Excludes shares issued upon conversion of Simple Agreement for Future Equity.”
  • On the use of proceeds: “None other than payments in the ordinary course of business.”

Signed by Merrill M. Mason, Attorney-in-Fact. Newest notice filed Aug 29, 2019 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • OrbitalRx, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2025).

    SEC Form D · Oct 2025

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Oct 2025

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of OrbitalRx, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by OrbitalRx, Inc.
NameRoleNamed in
Jason S. GasperExecutive officerOct 2025
Keith S. HeffronExecutive officerOct 2024
Nate PeatyExecutive officerOct 2024
Adam OrsbornExecutive officerAug 2019
Mayank ThanawalaExecutive officerAug 2019
Dan HackmanDirectorOct 2025
Gary S. AbrahamsDirectorOct 2025
Jason S. GasperDirectorOct 2025
Ren S. RoomeDirectorOct 2025
Robert CrutchfieldDirectorOct 2025
Nate PeatyDirectorOct 2024
Adam OrsbornDirectorAug 2019
David S. CarneyDirectorAug 2019